BARD1 has completed pilot studies to evaluate and optimise the BARD1-Lung biomarker panel and algorithm for detection of lung cancer.
These retrospective, case-control studies in lung cancer patients and healthy controls showed the accuracy of research BARD1-Lung panels at discriminating people with and without lung cancer, and the potential of developing a commercial BARD1-Lung test with high sensitivity and specificity for early detection of lung cancer.
Study results have demonstrated that BARD1-Lung has diagnostic accuracy of up to 0.86, 80% sensitivity and 77% specificity for detection of lung cancer. Additional promising results have been demonstrated for gender-specific algorithms.
Additional analytical and clinical validation studies are planned to further develop, optimise and validate BARD1-Lung for early detection of lung cancer.